GlaxoSmithKline PLC ADR (GSK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
GlaxoSmithKline PLC ADR stock (GSK) is currently trading at $51.84. GlaxoSmithKline PLC ADR PE ratio is 14.07. GlaxoSmithKline PLC ADR PS ratio (Price-to-Sales) is 3.19. Analyst consensus price target for GSK is $57.48. WallStSmart rates GSK as Moderate Buy.
- GSK PE ratio analysis and historical PE chart
- GSK PS ratio (Price-to-Sales) history and trend
- GSK intrinsic value — DCF, Graham Number, EPV models
- GSK stock price prediction 2025 2026 2027 2028 2029 2030
- GSK fair value vs current price
- GSK insider transactions and insider buying
- Is GSK undervalued or overvalued?
- GlaxoSmithKline PLC ADR financial analysis — revenue, earnings, cash flow
- GSK Piotroski F-Score and Altman Z-Score
- GSK analyst price target and Smart Rating
GlaxoSmithKline PLC ADR
📊 No data available
Try selecting a different time range
GSK Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · GlaxoSmithKline PLC ADR (GSK)
GSK trades at a significant discount to its Graham intrinsic value of $173.16, offering a 66% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
GlaxoSmithKline PLC ADR (GSK) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Overall metrics suggest strong investment potential with favorable risk/reward.
GlaxoSmithKline PLC ADR (GSK) Key Strengths (5)
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $43 in profit
Earnings per share surging 54.70% year-over-year
Large-cap company with substantial market presence
Strong profitability: $18 kept per $100 revenue
Supporting Valuation Data
GlaxoSmithKline PLC ADR (GSK) Areas to Watch (5)
Premium pricing at 4.9x book value
Modest revenue growth at 6.20%
Low institutional interest, mostly retail-driven
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 3.19x sales
GlaxoSmithKline PLC ADR (GSK) Detailed Analysis Report
Overall Assessment
This company scores 70/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 4.8/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Return on Equity, EPS Growth. Valuation metrics including PEG Ratio (0.50) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 43.30%, Profit Margin at 17.50%. Growth metrics are encouraging with EPS Growth at 54.70%.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, Institutional Own.. Some valuation metrics including Price/Sales (3.19), Price/Book (4.93) suggest expensive pricing. Growth concerns include Revenue Growth at 6.20%, which may limit upside. Profitability pressure is visible in Operating Margin at 18.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 43.30% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 6.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and Return on Equity makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for GlaxoSmithKline PLC ADR (GSK) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
GlaxoSmithKline PLC ADR is a mature, profitable business with steady cash generation. Revenue reached 32.7B with 6% growth year-over-year. Profit margins of 17.5% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 4330.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 1.5B in free cash flow and 2.0B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Dividend sustainability with a current yield of 3.4%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 23.9B is significantly higher than cash (4.4B). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact GlaxoSmithKline PLC ADR.
Bottom Line
GlaxoSmithKline PLC ADR is a well-established business delivering consistent profitability with 17.5% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 7:04:31 AM
About GlaxoSmithKline PLC ADR(GSK)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.